Clinical Trials on Hemoglobinuria in Poland

Total 13 results

AKARI Therapeutics

Terminated

rVA576 (Coversin) Long Term Safety and Efficacy Surveillance Study (CONSERVE)

Paroxysmal Nocturnal Hemoglobinuria

Poland
Alexion Pharmaceuticals

Terminated

Safety and Pharmacokinetics of TT30 in Subjects With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Paroxysmal Nocturnal Hemoglobinuria (PNH)

United States, Czech Republic, Italy, Poland, United Kingdom
Oregon Health and Science University

Completed

Microvascular and Cardiac Dysfunction in Paroxysmal Nocturnal Hemoglobinuria and Sickle Cell Disease

Sickle Cell Disease | Paroxysmal Nocturnal Hemoglobinuria | Rheologic Disease

United States
Apellis Pharmaceuticals, Inc.

Completed

A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients With PNH

Paroxysmal Nocturnal Hemoglobinuria

Hong Kong, Thailand, Malaysia, Singapore, Serbia, Peru, Philippines, Colombia, Mexico, Poland
Regeneron Pharmaceuticals

Recruiting

A Study in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate How Safe Long-term Treatment With Pozelimab + Cemdisiran Combination Therapy is and How Well it Works. (ACCESS-EXT)

Paroxysmal Nocturnal Hemoglobinuria

Taiwan, Korea, Republic of, Turkey, Spain, Thailand, Singapore, Japan, Canada, Malaysia, Poland, Italy
Alexion Pharmaceuticals, Inc.

Active, not recruiting

A Long-term Safety and Efficacy Study of Danicopan as an Add-on Therapy to Complement Component 5 Inhibitor (C5i) in Participants With PNH

Paroxysmal Nocturnal Hemoglobinuria

France, Italy, Spain, United States, Thailand, Korea, Republic of, United Kingdom, Israel, Czechia, Greece, Poland, Brazil, Japan, Canada, Malaysia
Alexion Pharmaceuticals, Inc.

Completed

ALXN1210 (Ravulizumab) Versus Eculizumab in Complement Inhibitor Treatment-Naïve Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Italy, United States, Taiwan, Thailand, Brazil, Russian Federation, United Kingdom, Belgium, Canada, Korea, Republic of, Poland, Malaysia, Japan, Czechia, Spain, Germany, Austria, France, Serbia, Mexico, Sweden, Estonia, Singapore, Ar... and more
Regeneron Pharmaceuticals

Recruiting

A C5 Inhibitor-controlled Study to Evaluate the Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Are Complement Inhibitor Treatment-Naive or Have Not Recently Received Complement Inhibitor Therapy (ACCESS-1)

Paroxysmal Nocturnal Hemoglobinuria

Mexico, Korea, Republic of, Turkey, Italy, United Kingdom, Thailand, Poland, Singapore, Spain, Taiwan, Canada, Japan, United States, Malaysia, Greece, Romania, Hungary
Hoffmann-La Roche
Chugai Pharmaceutical

Active, not recruiting

A Phase III Study Evaluating the Efficacy and Safety of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibitors. (COMMODORE 2)

Paroxysmal Nocturnal Hemoglobinuria

Spain, Korea, Republic of, France, Sweden, Thailand, Malaysia, China, Turkey, Netherlands, Japan, Australia, United Kingdom, Germany, South Africa, Brazil, Romania, Argentina, Poland, Greece, Hong Kong, Lithuania, Mexico, Philippines, Portuga... and more
Hoffmann-La Roche
Chugai Pharmaceutical

Recruiting

A Study Evaluating The Safety, Pharmacokinetics, and Efficacy Of Crovalimab Versus Eculizumab In Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors (COMMODORE 1)

Paroxysmal Nocturnal Hemoglobinuria

United States, Korea, Republic of, Spain, Germany, Estonia, Japan, Colombia, Saudi Arabia, Turkey, Brazil, France, Greece, Poland, Taiwan, Netherlands, Italy, Australia, Sweden, Singapore, Portugal, Hungary, Belgium, Canada, Czechia, Hong... and more
Alexion Pharmaceuticals, Inc.

Completed

Danicopan as Add-on Therapy to a C5 Inhibitor in Paroxysmal Nocturnal Hemoglobinuria (PNH) Participants Who Have Clinically Evident Extravascular Hemolysis (EVH)(ALPHA)

Paroxysmal Nocturnal Hemoglobinuria

France, Italy, Spain, United States, Taiwan, Thailand, Korea, Republic of, Japan, Malaysia, Brazil, Germany, Israel, Czechia, Netherlands, Greece, United Kingdom, Canada, Poland
Alexion Pharmaceuticals

Completed

Study of Safety in Hemolytic Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Treated With Eculizumab

Hemoglobinuria, Paroxysmal

United States, United Kingdom, Australia, Belgium, Canada, France, Germany, Ireland, Italy, Netherlands, Spain, Sweden, Switzerland
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute... and other collaborators

Recruiting

Treosulfan-Based Conditioning Regimen Before a Blood or Bone Marrow Transplant for the Treatment of Bone Marrow Failure Diseases (BMT CTN 1904)

Congenital Amegakaryocytic Thrombocytopenia | Paroxysmal Nocturnal Hemoglobinuria | Shwachman-Diamond Syndrome | Bone Marrow Failure Syndrome | Congenital Pure Red Cell Aplasia | Hereditary Sideroblastic Anemia | Hematologic Neoplasm With Germline GATA2 Mutation | Hematologic Neoplasm With Germline... and other conditions

United States

Clinical Trials on Hemoglobinuria in Poland

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Egypt

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations